866-997-4948(US-Canada Toll Free)

Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) - Pipeline Review, H2 2017

Published By :

Global Markets Direct

Published Date : Nov 2017

Category :

Pharmaceutical

No. of Pages : 152 Pages

Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) - Pipeline Review, H2 2017

Summary

According to the recently published report Tyrosine Protein Kinase JAK1 - Pipeline Review, H2 2017; Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) pipeline Target constitutes close to 29 molecules. Out of which approximately 29 molecules are developed by Companies.

Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) - JAK1 is a human tyrosine kinase protein essential for signaling for certain type I and type II cytokines. JAK1 plays a critical role in initiating responses to multiple major cytokine receptor families. Expression of JAK1 in cancer cells enables individual cells to contract, potentially allowing them to escape their tumor and metastasize to other parts of the body.

The report Tyrosine Protein Kinase JAK1 - Pipeline Review, H2 2017 outlays comprehensive information on the Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 6, 5, 7, 7 and 3 respectively. Report covers products from therapy areas Immunology, Dermatology, Oncology, Gastrointestinal, Musculoskeletal Disorders, Central Nervous System, Hematological Disorders, Respiratory, Cardiovascular and Ophthalmology which include indications Rheumatoid Arthritis, Ulcerative Colitis, Alopecia, Atopic Dermatitis, Diffuse Large B-Cell Lymphoma, Psoriasis, Psoriatic Arthritis, Vitiligo, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Ankylosing Spondylitis (Bekhterevs Disease), Autoimmune Disorders, B-Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia (CLL), Crohns Disease (Regional Enteritis), Graft Versus Host Disease (GVHD), Head And Neck Cancer Squamous Cell Carcinoma, Hodgkin Lymphoma (B-Cell Hodgkin Lymphoma), Mantle Cell Lymphoma, Multiple Sclerosis, Myelodysplastic Syndrome, Myelofibrosis, Peripheral T-Cell Lymphomas (PTCL), Relapsed Multiple Myeloma, Waldenstrom Macroglobulinemia, Anaplastic Large Cell Lymphoma (ALCL), Arthritis, Asthma, Auto Inflammatory Disease, B-Cell Chronic Lymphocytic Leukemia, Breast Cancer, Cancer Anorexia-Cachexia Syndrome, Chronic Asthma, Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia), Colorectal Cancer, Cutaneous Lupus Erythematosus, Cutaneous T-Cell Lymphoma, Dermatitis, Dermatomyositis, Endometrial Cancer, Eosinophilia, Essential Thrombocythemia, Follicular Lymphoma, Gastric Cancer, Giant Cell Arteritis, Hairy Cell Leukemia, Hypopharyngeal Cancer, Inflammation, Inflammatory Bowel Disease, Laryngeal Cancer, Lupus Erythematosus, Lupus Nephritis, Lymphoma, Marginal Zone B-cell Lymphoma, Melanoma, Metastatic Adenocarcinoma of The Pancreas, Metastatic Breast Cancer, Metastatic Prostate Cancer, Multiple Myeloma (Kahler Disease), Non-Hodgkin Lymphoma, Non-Small Cell Lung Cancer, Oral Cavity (Mouth) Cancer, Oropharyngeal Cancer, Pancreatic Ductal Adenocarcinoma, Parkinsons Disease, Plaque Psoriasis (Psoriasis Vulgaris), Post-Polycythemia Vera Myelofibrosis (PPV-MF), Refractory Acute Myeloid Leukemia, Refractory Multiple Myeloma, Relapsed Acute Myeloid Leukemia, Renal Cell Carcinoma, Respiratory Tract Inflammatory Disorders, Sicca Syndrome (Sjogren), Spondyloarthritis (Spondyloarthropathy), Systemic Lupus Erythematosus, Systemic-Onset Juvenile Idiopathic Arthritis (Still Disease), Thalassemia, Thrombocythemia Myelofibrosis, Transitional Cell Cancer (Urothelial Cell Cancer), Transitional Cell Carcinoma (Urothelial Cell Carcinoma) and Uveitis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2)
- The report reviews Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) targeted therapeutics and enlists all their major and minor projects
- The report assesses Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and its most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) - Overview 9
Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) - Therapeutics Development 10
Products under Development by Stage of Development 10
Products under Development by Therapy Area 11
Products under Development by Indication 12
Products under Development by Companies 18
Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) - Therapeutics Assessment 27
Assessment by Mechanism of Action 27
Assessment by Route of Administration 28
Assessment by Molecule Type 30
Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) - Companies Involved in Therapeutics Development 31
AbbVie Inc 31
Aclaris Therapeutics Inc 32
Astellas Pharma Inc 32
AstraZeneca Plc 32
Bristol-Myers Squibb Co 33
Chipscreen Biosciences Ltd 33
CJ HealthCare Corp 34
Concert Pharmaceuticals Inc 34
Eli Lilly and Co 35
Galapagos NV 35
Incyte Corp 36
Japan Tobacco Inc 38
Jiangsu Hengrui Medicine Co Ltd 39
Nissan Chemical Industries Ltd 39
Pfizer Inc 40
Portola Pharmaceuticals Inc 40
Sareum Holdings Plc 41
Theravance Biopharma Inc 42
Vectura Group Plc 42
Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) - Drug Profiles 44
ABBV-599 - Drug Profile 44
Product Description 44
Mechanism Of Action 44
R&D Progress 44
ATI-50001 - Drug Profile 45
Product Description 45
Mechanism Of Action 45
R&D Progress 45
ATI-50002 - Drug Profile 47
Product Description 47
Mechanism Of Action 47
R&D Progress 47
AZD-0449 - Drug Profile 48
Product Description 48
Mechanism Of Action 48
R&D Progress 48
AZD-1480 - Drug Profile 49
Product Description 49
Mechanism Of Action 49
R&D Progress 49
AZD-4205 - Drug Profile 51
Product Description 51
Mechanism Of Action 51
R&D Progress 51
baricitinib - Drug Profile 52
Product Description 52
Mechanism Of Action 52
R&D Progress 52
cerdulatinib - Drug Profile 64
Product Description 64
Mechanism Of Action 64
R&D Progress 64
CJ-15314 - Drug Profile 69
Product Description 69
Mechanism Of Action 69
R&D Progress 69
CS-944X - Drug Profile 70
Product Description 70
Mechanism Of Action 70
R&D Progress 70
CTP-543 - Drug Profile 71
Product Description 71
Mechanism Of Action 71
R&D Progress 71
filgotinib - Drug Profile 74
Product Description 74
Mechanism Of Action 74
R&D Progress 74
INCB-52793 - Drug Profile 87
Product Description 87
Mechanism Of Action 87
R&D Progress 87
itacitinib adipate - Drug Profile 88
Product Description 88
Mechanism Of Action 88
R&D Progress 88
JTE-052 - Drug Profile 92
Product Description 92
Mechanism Of Action 92
R&D Progress 92
NIP-565 - Drug Profile 94
Product Description 94
Mechanism Of Action 94
R&D Progress 94
peficitinib hydrobromide - Drug Profile 95
Product Description 95
Mechanism Of Action 95
R&D Progress 95
PF-04965842 - Drug Profile 98
Product Description 98
Mechanism Of Action 98
R&D Progress 98
PF-06700841 - Drug Profile 99
Product Description 99
Mechanism Of Action 99
R&D Progress 99
ruxolitinib phosphate - Drug Profile 101
Product Description 101
Mechanism Of Action 101
R&D Progress 101
SAR-20347 - Drug Profile 117
Product Description 117
Mechanism Of Action 117
R&D Progress 117
SART-29 - Drug Profile 119
Product Description 119
Mechanism Of Action 119
R&D Progress 119
SHR-0302 - Drug Profile 120
Product Description 120
Mechanism Of Action 120
R&D Progress 120
Small Molecules to Inhibit JAK1 and JAK3 for Autoimmune Diseases and Inflammation - Drug Profile 121
Product Description 121
Mechanism Of Action 121
R&D Progress 121
Small Molecules to Inhibit Jak1 for Oncology - Drug Profile 122
Product Description 122
Mechanism Of Action 122
R&D Progress 122
TD-1473 - Drug Profile 123
Product Description 123
Mechanism Of Action 123
R&D Progress 123
TD-3504 - Drug Profile 125
Product Description 125
Mechanism Of Action 125
R&D Progress 125
upadacitinib tartrate - Drug Profile 126
Product Description 126
Mechanism Of Action 126
R&D Progress 126
VR-588 - Drug Profile 132
Product Description 132
Mechanism Of Action 132
R&D Progress 132
Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) - Dormant Products 133
Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) - Discontinued Products 135
Tyrosine Protein Kinase JAK1 (Janus Kinase 1 or JAK1 or EC 2.7.10.2) - Product Development Milestones 137
Featured News & Press Releases 137
Oct 30, 2017: Lilly to Present New Data on its Anti-inflammatory Drug Candidate Baricitinib at ACR/ARHP Annual Meeting 137
Oct 24, 2017: AbbVie to Showcase New Data on Upadacitinib at the 2017 ACR/ARHP Annual Meeting 141
Oct 19, 2017: Concert Pharmaceuticals Announces PTAB Denies Incyte Petition Challenging CTP-543 Patent 142
Sep 14, 2017: Baricitinib Meets Primary Endpoint in Phase 2 Study of Patients with Moderate-to-Severe Atopic Dermatitis 142
Sep 11, 2017: Lilly to Present New Data for Olumiant (baricitinib) at the European Academy of Dermatology and Venereology (EADV) Annual Congress 143
Sep 11, 2017: Olumiant is accepted for restricted use within NHS Scotland 143
Sep 11, 2017: AbbVies Upadacitinib (ABT-494) Meets All Primary and Ranked Secondary Endpoints in Second Phase 3 Study in Rheumatoid Arthritis 144
Sep 07, 2017: AbbVies Upadacitinib (ABT-494) Meets Primary Endpoint in Phase 2b Study in Atopic Dermatitis 145
Aug 30, 2017: Lilly To File Baricitinib Resubmission To U.S. FDA Before End Of January 2018 147
Aug 08, 2017: Theravance Biopharma Reports Encouraging Data from First Cohort of Patients in Phase 1b Clinical Trial of TD-1473 in Ulcerative Colitis 147
Aug 02, 2017: Aclaris Therapeutics Submits Investigational New Drug Application for ATI-50002 to Treat Alopecia Areata 148
Jul 25, 2017: Lilly And Incyte Provide Update On Baricitinib 149
Jul 20, 2017: Incyte Announces First Patient Treated in Phase 3 Clinical Trial of Itacitinib for Acute Graft-Versus-Host Disease 149
Jul 10, 2017: FDA Lifts Clinical Hold on Concert Pharmaceuticals Clinical Trial with CTP-543 150
Jul 05, 2017: Galapagos: New Phase 2 study with filgotinib in non-infectious uveitis 150
Appendix 151
Methodology 151
Coverage 151
Secondary Research 151
Primary Research 151
Expert Panel Validation 151
Contact Us 151
Disclaimer 152

List of Tables
Number of Products under Development by Stage of Development, H2 2017 10
Number of Products under Development by Therapy Areas, H2 2017 11
Number of Products under Development by Indications, H2 2017 12
Number of Products under Development by Indications, H2 2017 (Contd..1), H2 2017 14
Number of Products under Development by Indications, H2 2017 (Contd..2), H2 2017 15
Number of Products under Development by Indications, H2 2017 (Contd..3), H2 2017 16
Number of Products under Development by Indications, H2 2017 (Contd..4), H2 2017 17
Number of Products under Development by Companies, H2 2017 18
Products under Development by Companies, H2 2017 19
Products under Development by Companies, H2 2017 (Contd..1), H2 2017 20
Products under Development by Companies, H2 2017 (Contd..2), H2 2017 21
Products under Development by Companies, H2 2017 (Contd..3), H2 2017 22
Products under Development by Companies, H2 2017 (Contd..4), H2 2017 23
Products under Development by Companies, H2 2017 (Contd..5), H2 2017 24
Products under Development by Companies, H2 2017 (Contd..6), H2 2017 25
Products under Development by Companies, H2 2017 (Contd..7), H2 2017 26
Number of Products by Stage and Mechanism of Actions, H2 2017 27
Number of Products by Stage and Route of Administration, H2 2017 29
Number of Products by Stage and Molecule Type, H2 2017 30
Pipeline by AbbVie Inc, H2 2017 31
Pipeline by Aclaris Therapeutics Inc, H2 2017 32
Pipeline by Astellas Pharma Inc, H2 2017 32
Pipeline by AstraZeneca Plc, H2 2017 33
Pipeline by Bristol-Myers Squibb Co, H2 2017 33
Pipeline by Chipscreen Biosciences Ltd, H2 2017 34
Pipeline by CJ HealthCare Corp, H2 2017 34
Pipeline by Concert Pharmaceuticals Inc, H2 2017 35
Pipeline by Eli Lilly and Co, H2 2017 35
Pipeline by Galapagos NV, H2 2017 36
Pipeline by Incyte Corp, H2 2017 37
Pipeline by Japan Tobacco Inc, H2 2017 39
Pipeline by Jiangsu Hengrui Medicine Co Ltd, H2 2017 39
Pipeline by Nissan Chemical Industries Ltd, H2 2017 40
Pipeline by Pfizer Inc, H2 2017 40
Pipeline by Portola Pharmaceuticals Inc, H2 2017 41
Pipeline by Sareum Holdings Plc, H2 2017 42
Pipeline by Theravance Biopharma Inc, H2 2017 42
Pipeline by Vectura Group Plc, H2 2017 43
Dormant Products, H2 2017 133
Dormant Products, H2 2017 (Contd..1), H2 2017 134
Discontinued Products, H2 2017 135
Discontinued Products, H2 2017 (Contd..1), H2 2017 136

List of Figures
Number of Products under Development by Stage of Development, H2 2017 10
Number of Products under Development by Therapy Areas, H2 2017 11
Number of Products under Development by Top 10 Indications, H2 2017 12
Number of Products by Stage and Mechanism of Actions, H2 2017 27
Number of Products by Routes of Administration, H2 2017 28
Number of Products by Stage and Routes of Administration, H2 2017 28
Number of Products by Stage and Molecule Type, H2 2017 30

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *